title: Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol.
authors.affiliation: Department of Dermatology, University of Würzburg, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Hornschuh
authors.forename: H
authors.initials: H
authors.lastname: Hamm
authors.forename: S
authors.initials: S
authors.lastname: Wever
authors.forename: T
authors.initials: T
authors.lastname: Hashimoto
authors.forename: U
authors.initials: U
authors.lastname: Schröder
authors.forename: E B
authors.initials: EB
authors.lastname: Bröcker
authors.forename: D
authors.initials: D
authors.lastname: Zillikens
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002990:Clobetasol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D019085:Fluorescent Antibody Technique, Direct; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D005938:Glucocorticoids; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010118:Oxytetracycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010391:Pemphigoid, Bullous / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction; D019233:Retreatment
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D007074:Immunoglobulin G; D009536:Niacinamide; D002990:Clobetasol; D010118:Oxytetracycline